NeuBase Therapeutics, Inc. stock is up 41.2% since 30 days ago. The next earnings date is Mar 12, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 19 February’s closed higher than January.
NeuBase Therapeutics, Inc. focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!